ART 34 AMDT

SUBSTITUTE CLAIMS

1. Use in the preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms of inflammation in a mammalian patient, of from about 500 to about 2.5 $x10^9$ synthetic peptide-carrying bodies selected from liposomes, solid beads, hollow beads and filled beads, the peptide-carrying bodies expressing having or expressible on the surface thereof an active group containing the peptide sequence RGD capable of being phagocytosed *in vivo* by mammalian antigen presenting cells resulting in the alteration of the cytokine profile of cells of the mammalian immune system, said bodies having a size from about 20 nanometers to 500 microns in diametric dimension.
2. Use as in claim 1 wherein the active peptide group is RGDS.
3. Use as in claim 1 or 2 for preparation of a medicament for alleviating or inhibiting the symptoms characteristic of a neurodegenerative disease wherein the number of bodies used to prepare the unit dosage of said bodies is from about 10,000 to about 50,000,000 bodies.
4. Use as in claim 1, claim 2 or claim 3 for preparation of a medicament for alleviating or inhibiting the symptoms characteristic of Parkinson's disease wherein the number of bodies used to prepare the unit dosage is from about 200,000 to about 10,000,000 bodies.

ART 34 AMDT

5. Use as in any preceding claim for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of a neurodegenerative disease.

6. Use as in claim 5 for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of a Parkinson's disease.

7. Use as in claim 5 for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of Alzheimer's disease.

8. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of cardiovascular disease.

9. Use as in claim 8 for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of atherosclerosis.

10. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of an autoimmune disease.

11. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for alleviating or inhibiting the symptoms characteristic of an endothelial dysfunction.

12. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for prophylaxis against oxidative stress.

13. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for prophylaxis against ischemia reperfusion injury.

ART 34 AMDT

14. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for prophylaxis against oxidative stress and ischemia reperfusion injury.

15. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for treatment and prophylaxis against amytrophic lateral sclerosis.

16. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for treatment and prophylaxis against congestive heart failure.

17. Use as in any of claims 1-4 for preparation of a unit dosage of a medicament for treatment and prophylaxis against Raynaud's disease.

18. Use as in any preceding claim for injection of said unit dosage of medicament intramuscularly or subcutaneously.

19. A process for alleviating or inhibiting the symptoms of inflammation in a mammalian patient, which comprises administering to the patient an effective amount of from about 500 to about 2.5×10^9 synthetic bodies having a three-dimensional core structure of size from 20 nanometers to 500 microns expressing or expressible on the surface thereof RGDS ligands which will react, optionally in the presence of adapter molecules, with at least one specific receptor wherein the binding of said ligand with said receptors produces an anti-inflammatory response *in vivo* in said mammal.